Sphera Funds Management’s SpringWorks Therapeutics SWTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-52,009
Closed -$2.3M 130
2025
Q1
$2.3M Sell
52,009
-47,991
-48% -$2.21M 0.53% 59
2024
Q4
$3.61M Buy
+100,000
New +$3.49M 0.65% 60
2024
Q3
Sell
-70,269
Closed -$2.65M 136
2024
Q2
$2.65M Hold
70,269
0.36% 77
2024
Q1
$3.46M Sell
70,269
-100,001
-59% -$4.62M 0.49% 61
2023
Q4
$6.21M Sell
170,270
-149,641
-47% -$3.91M 1% 40
2023
Q3
$7.4M Buy
319,911
+7,286
+2% +$199K 1.35% 19
2023
Q2
$8.2M Sell
312,625
-5,000
-2% -$131K 1.28% 20
2023
Q1
$8.18M Buy
317,625
+1,000
+0.3% +$29.2K 1.37% 22
2022
Q4
$8.24M Buy
316,625
+15,000
+5% +$370K 1.77% 16
2022
Q3
$8.61M Sell
301,625
-235,039
-44% -$6.74M 1.19% 21
2022
Q2
$13.2M Buy
536,664
+76,639
+17% +$2.8M 1.41% 15
2022
Q1
$26M Buy
460,025
+117,459
+34% +$6.72M 3.67% 9
2021
Q4
$21.2M Buy
342,566
+94,649
+38% +$6.26M 2.33% 10
2021
Q3
$15.7M Buy
247,917
+52,800
+27% +$4.07M 1.32% 14
2021
Q2
$16.1M Buy
195,117
+57,445
+42% +$4.36M 1.09% 26
2021
Q1
$10.1M Buy
137,672
+106,372
+340% +$8.33M 0.78% 28
2020
Q4
$2.27M Buy
+31,300
New +$2.01M 0.2% 83
2020
Q1
Sell
-200,000
Closed -$7.7M 96
2019
Q4
$7.7M Sell
200,000
-110,000
-35% -$2.57M 0.63% 33
2019
Q3
$6.72M Buy
+310,000
New +$7.33M 1.04% 29

Other funds holding SWTX

Sphera Funds Management's SWTX Position: Q2 2025 in Review

Sphera Funds Management sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 52,009 shares — an estimated $2.3M sold.

Sphera Funds Management first reported a position in SWTX in Q3 2019 and held it in 19 quarters. The position peaked at $26M in Q1 2022. 222 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • Sphera Funds Management reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Sphera Funds Management sold 52,009 SpringWorks Therapeutics shares in Q2 2025, an estimated $2.3M.
  • Sphera Funds Management first reported a position in SpringWorks Therapeutics in Q3 2019 and held it in 19 quarters.
  • Sphera Funds Management's SpringWorks Therapeutics position peaked at $26M in Q1 2022.
  • 222 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Sphera Funds Management's 13F filing for Q2 2025, filed 14 Aug 2025.